

JUL 31 2003 3:07PM

GLAXO WELLCOME

FAX RECEIVED

NO. 9876 P. 1

AUG 01 2003

FAX

CONFIDENTIAL GROUP 1600



GlaxoSmithKline

To Group 1624

Company USPTO

Fax 703-872-9306

From Allyson K. Jacobs

Tel 919-483-9105

Fax 919-483-7988

E-mail aki27836@glaxowellcome.com

Date 31-Jul-2003

Pages including cover 6

Subject Serial No.: 10/030,527

Filing Date: 1/9/02

Glaxo Wellcome Inc.
PO Box 13398
Five Moors Drive
Research Triangle Park
North Carolina 27709
Tel: 919 483 2100
www.gsk.com

Attached:

Amendment Transmittal
Response to Restriction
Certificate of Transmission

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

Received from <919 483 7988> at 7/31/03 2:27:54 PM [Eastern Daylight Time]

PTO/SB/97 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the
United States Patent and Trademark Officeon 7/31/03
DateAllyson K. Jacobs
SignatureAllyson K. Jacobs
Typed or printed name of person signing CertificateNote: Each paper must have its own certificate of transmission, or this certificate must identify
each submitted paper.

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

AMENDMENT TRANSMITTAL LETTER (Large Entity)				Docket No. PU3743USW	
Applicant(s): Cockerill et al.					
Serial No. 10/030,527	Filing Date 1/9/02	Examiner T. Truong	Group Art Unit 1624		
Invention: ANILINOQUINAZOLINES AS PROTEIN TYROSINE KINASE INHIBITORS					
<u>TO THE COMMISSIONER FOR PATENTS:</u>					
Transmitted herewith is an amendment in the above-identified application. The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	43	43	0 x	\$18.00	\$0.00
INDEP. CLAIMS	1	3	0 x	\$84.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00
 <input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 07-1392 <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.					
 _____ Signature John L. Lemanowicz, Reg. No. 37,380 Attorney for Applicants GlaxoSmithKline Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709-3398 Telephone: (919) 483-8247 Facsimile: (919) 483-7988			Dated: 31 July 2003		
CC:			<div style="text-align: center;">I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.</div> <div style="text-align: center; margin-top: 10px;">_____ Signature of Person Mailing Correspondence</div> <div style="text-align: center; margin-top: 10px;">_____ Typed or Printed Name of Person Mailing Correspondence</div>		

P111LARGE/REV06

JUL 31 2003 3:07PM

Atty. Docket No.: PU374303v

GLAXO WELLCOME

NO. 9876 P. 3

#6
8/15/03
C. Styles

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Cockerill et al

Serial No.: 10/030,527

Examiner: T. Truong

Filing Date: January 9, 2002

Art Unit: 1624

For: ANILINOQUINAZOLINES AS PROTEIN TYROSINE KINASE INHIBITORS

Commissioner for Patents

Washington D.C. 20231

RESPONSE TO RESTRICTION

Sir:

This paper is submitted in response to the Office Action mailed July 2, 2003, for which a 1-month shortened statutory period to respond was set. Accordingly, this paper is timely filed on or before August 2, 2003. Early examination of the application on the merits is earnestly solicited.

Remarks being on page 2 of this paper.